LATEST NEWS
New Publication - SG2285 A Novel Antitumour ProdrugTue 22nd Jun 10
John A. Hartley et.al (2010 In press) SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dime
LATEST PRESS RELEASE
Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000Thu 8th Oct 09
London, United Kingdom, 08 October, 2009 - Spirogen Limited (Spirogen), the UK-based developer of DN
SECURE AREA
A clinical stage Biotechnology company creating potent small molecules based on novel mechanisms and chemistry to target important cancers.
The company has significant experience utilizing cutting edge technologies to make effective DNA sequence targeted agents.